{"entity":{"id":"cullgen","kind":"company","name":"Cullgen","aka":[],"tldr":"Cullgen designs drugs that tag disease-causing proteins for destruction by the cell's own recycling system, and links such drugs to antibodies. In May 2026 it became part of Gyre Therapeutics, a US and China company focused on fibrosis.","summary":"Cullgen is a San Diego clinical-stage biopharmaceutical company developing targeted protein degraders (TPDs) and degrader-antibody conjugates (DACs) for cancer, pain and inflammatory diseases, positioning DACs as the next generation of antibody-drug conjugates. Its discovery work uses novel E3 ligase ligands beyond cereblon and has operations in both the United States and China. On 2 March 2026 Nasdaq-listed Gyre Therapeutics (GYRE) agreed to acquire Cullgen in an all-stock transaction valued at about 300 million US dollars; the deal closed on 4 May 2026, Cullgen became a wholly owned subsidiary and its chief executive, Ying Luo, became president and chief executive of Gyre. Gyre describes the combined company as a US- and China-based, fully integrated biopharmaceutical company with a fibrosis-first commercial business and a degrader and DAC discovery engine.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cullgen.com/"},{"label":"Gyre completes acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_ex99-1.htm"},{"label":"Gyre agreement announcement (PDF on Cullgen site)","url":"https://www.cullgen.com/s/Cullgen-Gyreagreementpressrelease-4c4h.pdf"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","adcs"],"technologies":["protac-degrader","degrader-antibody-conjugate"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Cullgen's pipeline page returned 404, so individual programme names (for example its TRK degrader) and clinical phases are not recorded. Pre-acquisition venture rounds were not found in SEC Form D searches. Headquarters recorded as San Diego per the company site; the group has substantial China operations but is not headquartered in mainland China."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.cullgen.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2026,"amountUsd":300000000,"source":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_ex99-1.htm","note":"All-stock transaction valued at approximately 300 million US dollars; announced 2 March 2026, closed 4 May 2026"}]},"route":"/companies/cullgen/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"degrader-antibody-conjugate","kind":"technology","name":"Degrader-antibody conjugate (DAC)","route":"/technologies/degrader-antibody-conjugate/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}]}}